HomeOur ProjectsHepC in NYC

HepC in NYC

Overview:

Addressing HCV-related hepatocellular carcinoma: the current and future epidemics.” Hepatitis C virus (HCV)-related deaths now exceed HIV-related deaths in the US. Throughout the world, HCV is hyperendemic in people who inject drugs (PWID). New outbreaks of acute HCV infection are unfolding in HIV-positive men who have sex with men (MSM) and in 15-24 year olds who have transitioned from abuse of prescription opioids to illicit opiate injection. In patients with chronic HCV infection, 20-25% will develop liver disease which may manifest as cirrhosis, liver failure or hepatocellular carcinoma (HCC). The prognosis for HCC is extremely poor, and HCV is the chief etiologic agent for this type of cancer. Recent discoveries in HCV prevention and treatment provide a great opportunity to reverse the trend toward increasing rates of HCV, HCV/HIV co-infection, and HCC. This study will use the methods of Implementation Science – research synthesis, mathematical modeling and simulation, and comparative effectiveness analyses – to determine how best to constitute a portfolio of interventions for the prevention and control of HCV and its consequences while taking into account limited resources and underlying epidemiologic and social network features. A dissemination plan will make extensive use of technology, including social media, and guidance from key stakeholders.

Featured News
Latest News

Last week, an article about my research, written by Joseph Brean, appeared in the Canadian newspaper The National Post. Considering the reputation of the Postmedia Network, I was skeptical as soon as he contacted me, so before agreeing to do the interview, one of the first questions I asked was whether

The REACH lab's Minority Health Disparities Initiative (MHDI) project has partnered with other community organizations on an exhibit at the Nebraska History Museum called "Looking Past Skin: Our Common Threads." The exhibit will be located on the third floor of the museum which is at the intersection of P Street and

REACH researchers Roberto Abadie, Bilal Khan, and Kirk Dombrowski recently contributed to a paper published in the December issue of Drug and Alcohol Dependence. The study's aim was to examine substance use and polysubstance use behaviors in Puerto Rico's PWID communities. Polysubstance use is defined as "consumption of two or more substances

Members of the REACH lab published a paper in Substance Use and Misuse in November titled "Injection Partners, HCV, and HIV Status among Rural Persons Who Inject Drugs in Puerto Rico." REACH researchers Patrick Habecker, Roberto Abadie, and Kirk Dombrowski set out to identify network risks associated with injection partners and the contraction

Project Details

Addressing HCV-related hepatocellular carcinoma: the current and future epidemics.” Hepatitis C virus (HCV)-related deaths now exceed HIV-related deaths in the US. Throughout the world, HCV is hyperendemic in people who inject drugs (PWID). New outbreaks of acute HCV infection are unfolding in HIV-positive men who have sex with men (MSM) and in 15-24 year olds who have transitioned from abuse of prescription opioids to illicit opiate injection. In patients with chronic HCV infection, 20-25% will develop liver disease which may manifest as cirrhosis, liver failure or hepatocellular carcinoma (HCC). The prognosis for HCC is extremely poor, and HCV is the chief etiologic agent for this type of cancer. Recent discoveries in HCV prevention and treatment provide a great opportunity to reverse the trend toward increasing rates of HCV, HCV/HIV co-infection, and HCC. This study will use the methods of Implementation Science – research synthesis, mathematical modeling and simulation, and comparative effectiveness analyses – to determine how best to constitute a portfolio of interventions for the prevention and control of HCV and its consequences while taking into account limited resources and underlying epidemiologic and social network features. A dissemination plan will make extensive use of technology, including social media, and guidance from key stakeholders.

“Addressing HCV-related hepatocellular carcinoma: the current and future epidemics” is funded by the National Institute of Drug Abuse, R01 DA034637-01 under the direction of Holly Hagan, Principal Investigator, New York University, from July 2013-June 2017.[

The leader of this work at REACH is Kirk Dombrowski, who will work closely with Bilal Khan, and Mohamed Saad at CUNY to implement the simulation portion of the project using the MABUSE platform.